Publications by authors named "Helen Tomkinson"

Claim this Profile
P
Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung Cancer.
Martin Johnson, Yu-Wei Lin, Henning Schmidt, Mikael Sunnaker, Eline Van Maanen, Helen Tomkinson

Pharmacol Res Perspect· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response modelling of osimertinib in patients with non-small cell lung cancer.
Martin Johnson, Yu-Wei Lin, Henning Schmidt, Mikael Sunnaker, Eline Van Maanen, Helen Tomkinson

Br J Clin Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vitro PK/PD modeling of tyrosine kinase inhibitors in non-small cell lung cancer cell lines.
Linda Wanika, Neil D Evans, Martin Johnson, Helen Tomkinson, Michael J Chappell

Clin Transl Sci· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Longitudinal Circulating Tumor DNA Modeling to Predict Disease Progression in First-Line Mutant Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer.
Martin Johnson, Carlos Serra Traynor, Karthick Vishwanathan, Philip Overend, Ryan Hartmaier, Helen Tomkinson

Clin Pharmacol Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic/Pharmacodynamic Analysis of Savolitinib plus Osimertinib in an EGFR Mutation-Positive, MET-Amplified Non-Small Cell Lung Cancer Model.
Rhys D O Jones, Klas Petersson, Areya Tabatabai, Larry Bao, Helen Tomkinson

Mol Cancer Ther· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors.
Shringi Sharma, Xavier Pepin, Harini Burri, Lianqing Zheng, Nataliya Kuptsova-Clarkson, Helen Tomkinson

Clin Pharmacol Drug Dev· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects.
Shringi Sharma, Xavier Pepin, Jean Cheung, Lianqing Zheng, Hua Wei, Helen Tomkinson

Br J Clin Pharmacol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Exposure-response analysis of acalabrutinib and its active metabolite, ACP-5862, in patients with B-cell malignancies.
Helena Edlund, Núria Buil-Bruna, Karthick Vishwanathan, Helen Wei, Rakesh Raman, Helen Tomkinson

Br J Clin Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concentration-QT modelling in early clinical oncology settings: Simulation evaluation of performance.
Gael Cantet, Alienor Berges, Rhianna O'Sullivan, Sarit Cohen-Rabbie, Corina Dota, Helen Tomkinson

Br J Clin Pharmacol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approach.
Helena Edlund, Francesco Bellanti, Huan Liu, Karthick Vishwanathan, Helen Tomkinson

Br J Clin Pharmacol· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imputing Biomarker Status from RWE Datasets-A Comparative Study.
Carlos Traynor, Tarjinder Sahota, Helen Tomkinson, Ignacio Gonzalez-Garcia, Neil Evans

J Pers Med· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose Regimens.
Sarit Cohen-Rabbie, Li Zhou, Karthick Vishwanathan, Martin Wild, Sherrie Xu, Helen Tomkinson

J Clin Pharmacol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QT Prolongation Risk Assessment in Oncology: Lessons Learned From Small-Molecule New Drug Applications Approved During 2011-2019.
Sarit Cohen-Rabbie, Alienor C Berges, Dinko Rekić, Joanna Parkinson, Corina Dota, Helen K Tomkinson

J Clin Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Stein Schalkwijk, Li Zhou, Sarit Cohen-Rabbie, Lokesh Jain, Tomoko Freshwater, Helen Tomkinson

Cancer Chemother Pharmacol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology Patients.
Diansong Zhou, Jianguo Li, Maria Learoyd, Khanh Bui, Alienor Berges, Helen Tomkinson

Clin Pharmacol Ther· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients.
Diansong Zhou, Jianguo Li, Khanh Bui, Maria Learoyd, Alienor Berges, Helen Tomkinson

Clin Pharmacokinet· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancer.
Toshio Kawata, Mitsuo Higashimori, Yohji Itoh, Helen Tomkinson, Martin G Johnson

Cancer Chemother Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Food Effect Study Design With Oral Drugs: Lessons Learned From Recently Approved Drugs in Oncology.
Mark Farha, Eric Masson, Helen Tomkinson, Ganesh Mugundu

J Clin Pharmacol· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population Pharmacokinetic and Exposure-Response Analysis of Selumetinib and Its N-desmethyl Metabolite in Patients With Non-Small Cell Lung Cancer.
Xiao Tong, Hongmei Xu, David J Carlile, Helen Tomkinson, Nidal Al-Huniti

J Clin Pharmacol· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Harnessing Meta-analysis to Refine an Oncology Patient Population for Physiology-Based Pharmacokinetic Modeling of Drugs.
Emily Schwenger, Venkatesh Pilla Reddy, Ganesh Moorthy, Pradeep Sharma, Helen Tomkinson

Clin Pharmacol Ther· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model.
Yuri Kosinsky, Simon J Dovedi, Kirill Peskov, Veronika Voronova, Lulu Chu, Helen Tomkinson

J Immunother Cancer· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug-disease modeling in the pharmaceutical industry - where mechanistic systems pharmacology and statistical pharmacometrics meet.
Gabriel Helmlinger, Nidal Al-Huniti, Sergey Aksenov, Kirill Peskov, Karen M Hallow, Helen Tomkinson

Eur J Pharm Sci· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of the Pharmacokinetics of the Phase II and Phase III Capsule Formulations of Selumetinib and the Effects of Food on Exposure: Results From Two Randomized Crossover Trials in Healthy Male Subjects.
Helen Tomkinson, Eileen McBride, Paul Martin, Eleanor Lisbon, Angela W Dymond

Clin Ther· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Jeffrey R Infante, Roger B Cohen, Kevin B Kim, Howard A Burris, Gregory Curt, Helen K Tomkinson

Invest New Drugs· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.
Jeffrey R Infante, Roger B Cohen, Kevin B Kim, Howard A Burris, Gregory Curt, Helen K Tomkinson

Invest New Drugs· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis